Crisis Means Opportunity? Lessons From Chinese API Maker’s Rapid Downfall
With its stock plunging 20% over three trading days, Chinese bulk producer Zhejiang Huahai has been hit hard by a spreading worldwide recall of its big-selling valsartan active ingredient, but the issue has also thrown into relief other underlying issues.
You may also be interested in...
EU Regulators Recall Valsartan Products Produced In China
Stada and Accord are among the companies affected by an EU wide recall of valsartan manufactured by a Chinese supplier.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.